Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD

We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber, to discuss his paper in the NEJM “Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma”.

Pembrolizumab is Merck’s Keytruda and one of the promising new checkpoint inhibitors. Used in combination with immunotherapy and other checkpoint inhibitors, results are improving in treating some tumors.

This entry was posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology. Bookmark the permalink.

Leave a Reply

Your email address will not be published.